Tayside drugs specialist inks Sanofi partnership

Dundee-based Exscientia has struck a drug discovery partnership with global pharma company Sanofi that could generate substantial financial returns.
By The Newsroom
Published 10th May 2017, 08:02 BST
Updated 10th May 2017, 16:17 BST

This article contains affiliate links. We may earn a small commission on items purchased through this article, but that does not affect our editorial judgement.

Exscientia uses artifcial intelligence in the field of drug discovery. Picture: Ian Waldie/Getty ImagesExscientia uses artifcial intelligence in the field of drug discovery. Picture: Ian Waldie/Getty Images
Exscientia uses artifcial intelligence in the field of drug discovery. Picture: Ian Waldie/Getty Images

The Scots firm, which is at the forefront of artificial intelligence-driven drug discovery, said the research collaboration and licence option agreement with Sanofi was focused on the area of metabolic disease.

Own an innovative start-up? Find out how to win £5,000 for your business

Hide Ad
Hide Ad

Exscientia will receive ongoing research funding and could receive up to €250 million (£210m) in success-based payments if certain development milestones are achieved.

200 Voices: find out more about the people who have shaped Scotland

Chief executive Andrew Hopkins said: “Sanofi has put together an excellent experimental backbone for this collaboration and we look forward to delivering high-value projects for the company.”

Any licensed products reaching the market will qualify for recurrent sales milestones.

Click here to ‘Like’ The Scotsman Business on Facebook

Related topics:DundeeFacebookScotland